How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?

Abstract Despite an increasing desire to use historical cohorts as “synthetic” controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular chara...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Ing Soo Tiong, Meaghan Wall, Ashish Bajel, Akash Kalro, Shaun Fleming, Andrew W. Roberts, Nisha Thiagarajah, Chong Chyn Chua, Maya Latimer, David Yeung, Paula Marlton, Amanda Johnston, Anoop Enjeti, Chun Yew Fong, Gavin Cull, Stephen Larsen, Glen Kennedy, Anthony Schwarer, David Kipp, Sundra Ramanathan, Emma Verner, Campbell Tiley, Edward Morris, Uwe Hahn, John Moore, John Taper, Duncan Purtill, Pauline Warburton, William Stevenson, Nicholas Murphy, Peter Tan, Ashanka Beligaswatte, Howard Mutsando, Mark Hertzberg, Jake Shortt, Ferenc Szabo, Karin Dunne, Andrew H. Wei, Australasian Leukaemia and Lymphoma Group (ALLG)
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Publishing Group 2024-03-01
Serija:	Blood Cancer Journal
Online dostop:	https://doi.org/10.1038/s41408-024-00996-x
Oznake:	Označite Brez oznak, prvi označite!